AllergyTalk: Food Allergy Frontlines: Clarifying Diagnosis, Advancing Treatment - Episode 2: Immunotherapy for IgE-Mediated Food Allergy: OIT, SLIT & EPIT (Not for CME)

Food allergy is a complex and potentially life-threatening condition that requires a multidisciplinary approach to diagnosis, prevention, and treatment. Yet confusion persists among clinicians regarding the accurate identification and management of food allergies, particularly in differentiating between IgE-mediated reactions, non-IgE-mediated allergies, and food intolerances. Simultaneously, rapid advancements in therapy—including immunotherapies and biologics—are creating new opportunities for proactive and personalized care.

The traditional approach of allergen avoidance is being redefined with FDA-approved and emerging immunotherapies. This episode explains the differences between oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT), focusing on indications, efficacy, safety, and patient selection—empowering clinicians to engage in shared decision-making and facilitate appropriate referrals.

Host: Gerald Lee, MD, FACAAI
Experts: Edwin H. Kim, MD, FACAAI; Julie Wang, MD, FACAAI

This episode is not eligible for CME.

References:

  1. Bartha, I., Almulhem, N., & Santos, A. F. (2024). Feast for thought: A comprehensive review of food allergy 2021-2023. The Journal of allergy and clinical immunology, 153(3), 576–594.
  2. Anagnostou, A., Greenhawt, M., Shaker, M., Vickery, B. P., & Wang, J. (2025). Food allergy yardstick: Where does omalizumab fit?. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology, 134(1), 110–121.

This podcast series is supported by Genentech.

Target Audience

Allergists and immunologists, Pediatricians, Internists and family medicine physicians, Nurse practitioners and physician assistants in primary care.

Learning Objectives

After listening to this podcast miniseries, participants should be better able to:

  1. Distinguish between IgE-mediated and non-IgE-mediated food allergies and food intolerances.
  2. Apply current evidence-based guidelines for early food allergy prevention and diagnosis.
  3. Describe the clinical application of oral, sublingual, and epicutaneous immunotherapy for food allergy.
  4. Evaluate the role of biologic therapies, such as omalizumab, in the management of complex or refractory food allergy cases.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary
Course opens: 
01/09/2026
Course expires: 
12/31/2027
Rating: 
0

Gerald Lee, MD, FACAAI
Nothing relevant to disclose.

Julie Wang, MD, FACAAI
Nothing relevant to disclose.

Edwin H. Kim, MD, FACAAI
Nothing relevant to disclose.

Please login or create an account to take this course.